For anyone in Okni looking to source CJC-1295, the key fact to understand is that this compound moves through online research channels. The key implication for Okni researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the quality verification approach is universal across all locations. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis containing HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. This guide takes Okni researchers through that evaluation process and explains how to verify CJC-1295 vendor quality step by step.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Okni researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying CJC-1295: Quality Markers to Look For
Evaluating CJC-1295 vendors starts with the COA: locate the batch-specific certificate before purchasing, not after. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from bacterial cell wall components can trigger serious immune reactions even at very low concentrations. Community reputation in research forums is a complementary signal to COA verification — vendors with consistently positive reports over 12+ months have built their reputation on real product performance. Hold lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order CJC-1295 — ships to Okni
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human use by the FDA or comparable health authorities — all information here is provided for educational purposes. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — equivalent to 25mcg per unit on an insulin syringe. Quality CJC-1295 sourcing is inseparable from safety — bacterial endotoxin contamination, wrong peptide identity, and degraded material are all safety issues that rigorous vendor evaluation eliminates. PubMed and related preprint servers are the primary literature resources for CJC-1295 research; favour indexed journal publications over preprints over unreviewed preprints or forum reports.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
